• neurological
  • This study, which has the statistical power to detect differences in developmental quotient as small as five points, gave no evidence that at 2 years cytomegalovirus infection was associated with mental retardation in the absence of other neurological impairment. (bmj.com)
  • Efficacy
  • A phase 2 study of a recombinant gB subunit CMV-vaccine published in 2009 indicated an efficacy of 50% in seronegative women of childbearing age-thus the protection provided was limited and a number of subjects contracted CMV infection despite the vaccination. (wikipedia.org)
  • Trial
  • In 2013, Astellas Pharma has started on individuals who received a hematopoietic stem cell transplant a Phase III trial with its CMV deoxyribonucleic acid DNA cytomegalovirus vaccine ASP0113. (wikipedia.org)
  • In 2015, Astellas Pharma has commenced on healthy volunteers a Phase I trial with its cytomegalovirus vaccine ASP0113. (wikipedia.org)
  • TEXT
  • Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. (wikipedia.org)